Trametinib has not demonstrated a better clinical activity compared to docetaxel in a randomized phase II study conducted on KRAS mutant NSCLC patients (87); trametinib has also been evaluated in phase I/Ib trials in combination with docetaxel or pemetrexed in patients with NSCLC, showing a favorable toxicity profile and a slightly better activity on patients with KRAS mutation compared to KRAS wild-type patients (88, 89). This evidence concerns the gene KRAS and non-small cell lung carcinoma.